The variant NM_001005361.3:c.1564C>T in DNM2 is a missense variant predicted to cause substitution of arginine by cysteine at amino acid 522 (p.Arg522Cys). The highest population minor allele frequency in gnomAD v4.1.0 is 8.526e-7 (1/1172834 alleles) in non-Finnish European which meets PM2_Supporting. DNM2, in which the variant was identified, is defined by the ClinGen Congenital Myopathies VCEP as a gene that has a low rate of benign missense variation and where pathogenic missense variants are a common mechanism of disease (PP2). The REVEL computational prediction analysis tool produced a score of 0.746, which is above the threshold of 0.7, evidence that correlates with impact to DNM2 function (PP3). Two different missense variants, p.Arg522His and p.Arg522Leu (ClinVar IDs: 158514 and 373110), in the same codon have been classified as (likely) pathogenic on ClinVar, of which p.Arg522His has been classified as pathogenic for centronuclear myopathy by the ClinGen Congenital Myopathies VCEP (PM5). This variant has been reported in one proband with centronuclear myopathy who presented with predominantly distal muscle weakness, ptosis, ophthalmoplegia/ paresis, facial weakness, weak deep tendon reflexes, stepping gait, central nuclei, fiber hypotrophy, and Type 1 fiber predominance (0.25pts, PS4_Supporting; PMID: 22396310). In summary, the variant meets criteria to be classified as likely pathogenic for centronuclear myopathy. ACMG/AMP criteria met, as specified by the ClinGen Congenital Myopathies VCEP: PM5, PS4_Supporting, PM2_Supporting, PP2, PP3 (ClinGen Congenital Myopathies VCEP specifications version 1.0.0; September 8th, 2025).